Monitor for heart failure after breast-cancer chemotherapy: study

Attention drawn to trastuzumab and anthracyclines

Cardiac monitoring should be routine in breast cancer patients treated with certain chemotherapeutic agents, especially trastuzumab and anthracyclines, US researchers say.

Cardiotoxicity associated with the use of chemotherapy in more than 16,000 women with breast cancer , 4325 of whom received trastuzumab was analysed by researchers from the University of Texas.

Overall, 4.2% of women developed heart failure a median of eight months after chemotherapy. The rate was significantly higher among women treated with trastuzumab (8.3%) than among those